Clinical trial of nafoxidine in advanced breast cancer.

Abstract

Forty-nine postmenopausal patients with advanced breast cancer were treated with a nonsteroidal antiestrogen, Nafoxidine. The drug was generally well tolerated with dermatitis being the major toxic effect. A partial response in 12 of 40 patients, or 30%, was achieved with a median duration of response of greater than five months.

• Authors: F L Steinbaum, R L De Jager, I H Krakoff
• Journal: Medical and pediatric oncology (Med Pediatr Oncol) Vol. 4 Issue 2 Pg. 123-6 ( 1978) ISSN: 0098-1532 [Print] United States
• PMID: 661750 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Pyrrolidines
• Receptors, Estrogen
• Nafoxidine
• Prednisone

Topics

• Adult
• Aged
• Breast Neoplasms (drug therapy)
• Drug Hypersensitivity (etiology)
• Drug Therapy, Combination
• Female
• Humans
• Middle Aged
• Nafoxidine (adverse effects, therapeutic use)
• Neoplasm Metastasis (drug therapy)
• Neoplasm Recurrence, Local (drug therapy)
• Prednisone (therapeutic use)
• Pyrrolidines (therapeutic use)
• Receptors, Estrogen (drug effects)